Also, the CDK4/6 inhibitors combined with endocrine therapy (ET) did not prolong the overall survival of patients with advanced bone-only metastasis compared with ET alone, so “bone-only metastasis (HR, 1.22; 95% CI, 0.88-1.68; P < .001)” should be removed from the Results section of the Abstract, “and bone-only disease” should be removed from the fifth paragraph of the Discussions section, and “bone-only metastasis” should be removed from the Conclusion section. The gene discussed is CDK4; the disease is metastasis.